News Presentations Publications

FILTERS

TOPICS

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac) in a Rodent Model

Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The … Continued

More >

Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

Suspensions of submicron particle taxanes (Figure 1) allow for direct administration of high, sustained levels of chemotherapeutics at the site … Continued

More >

CritiTech PES partner NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer

NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor … Continued

More >

CritiTech PES partner NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* … Continued

More >

Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy

The combination of chemotherapies and immunotherapies highlights the significance of small molecule drug development as an ongoing treatment modality. Although … Continued

More >

CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019

FOR IMMEDIATE RELEASEOctober 24, 2018 CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019 CritiTech Particle Engineering Solutions was … Continued

More >

CritiTech Particle Engineering Solutions Launches New Pharmaceutical Spray Drying Business

FOR IMMEDIATE RELEASEMay 30, 2018 LAWRENCE, KS – CritiTech Particle Engineering Solutions, a growing Contract Development Manufacturing Organization (CDMO) and … Continued

More >

NanOlogy to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting

Update – 6/4/18:  Link to NanOlogy Poster presented at 2018 ASCO Annual Meeting Studies of Inhaled NanoPac Show Prolonged Retention … Continued

More >

New Cancer Answer

FORT WORTH, Texas—Researchers have been trying to develop therapeutic agents powerful enough to destroy tumors without harmful effects to healthy … Continued

More >

NanOlogy Takes Nanoparticle Tech into Phase II Trials

OCTOBER 16, 2017 BY SARAH FAULKNER In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with … Continued

More >